Bio-Tissue™ Trending At 35 Percent Compound Growth, 33 Percent Unit Growth

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MIAMI--(BUSINESS WIRE)--Bio-Tissue™, Inc., the industry leader in regenerative tissue therapies for ocular surface diseases and disorders, today announced it has attained 33 percent unit growth and a 7-year compounded annual growth rate (CAGR) of 35 percent. With nearly 200,000 units shipped across all product lines since 2006 and more than 150,000 successful human transplantations, Bio-Tissue’s products are used by eye care professionals worldwide to manage ocular surface diseases and conditions.

Help employers find you! Check out all the jobs and post your resume.